Navigation Links
Study Puts 1 Alzheimer's Theory in Doubt
Date:8/20/2007

Results in mice suggest a key gene might not be to blame, researchers say

MONDAY, Aug. 20 (HealthDay News) -- Research with mice is poking holes in a prevailing theory on the origins of Alzheimer's, scientists say.

Mice without a gene thought to rein in cell-damaging free radicals actually had fewer Alzheimer's-linked brain plaques than mice with the gene.

"This finding may go beyond Alzheimer's into all aging theory," noted lead researcher Carlos T. Moraes, an associate professor of neurology and cell biology and anatomy at the University of Miami Miller School of Medicine.

The study is published in this week's early edition of the journal Proceedings of the National Academy of Sciences.

Moraes said that, right now, "nobody knows what causes Alzheimer's disease," which affects more than 4.5 million Americans according to the National Institutes of Health.

However, one leading hypothesis is that there is a defect in the mitochondrial energy production system in cells, Moraes explained. The mitochondria are the cell's "power houses," giving it the energy it needs to function.

In prior studies, examination of the brain cells of people with Alzheimer's found some defects in an enzyme produced by the cytochrome c oxidase (COX) gene, which is important for mitochondrial energy production.

In addition, so-called "free radicals," which cause oxidative stress, are produced in the cell's mitochondria, Moraes noted. "It was assumed that when you have a problem with the COX gene, you have more free radicals being formed," he said.

To see how the gene worked, Moraes's group removed the COX10 gene in mice engineered to develop Alzheimer's disease.

"We expected to see that these animals would have more amyloid plaques," Moraes said. "But we got the opposite result," he said.

The animals without the COX10 gene actually developed fewer brain plaques than those with the gene, Moraes said. "Those animals also had less free radicals," he said.

The findings suggest that a defect in the COX10 gene develops after amyloid plaques develop, not the other way around, as has been thought, Moraes said.

"The mitochondrial defect in Alzheimer's disease appears to be a consequence of amyloid accumulation, not the cause of amyloid accumulation," he said. "Also, if you have a defect in the COX gene, you are not necessarily going to have more free radicals being formed," he added.

According to Moraes, the finding could have implications for scientists' understanding of the aging brain in general, not just Alzheimer's.

If the findings are duplicated in other research, they might be useful in developing new treatments for Alzheimer's -- treatments that target the COX gene, Moraes said.

One expert agreed that the findings shed new light on Alzheimer's disease.

"This study shows that a genetic manipulation that reduced the activity of a key energy-producing enzyme also reduced free radical damage and Alzheimer pathology in a mouse model," said Greg M. Cole, a neuroscientist at the Greater Los Angeles VA Healthcare System and associate director of the Alzheimer's Disease Research Center at UCLA's David Geffen School of Medicine.

"The results are consistent with other evidence that reducing free radicals can limit Alzheimer amyloid plaque pathology," Cole added. "Examples include reducing caloric intake or increasing antioxidant intake. So, even though clinical trials to treat Alzheimer's with [antioxidant] vitamin E have been disappointing, earlier and more effective reduction of free radical damage could mimic the success of this genetic approach and should still be pursued," he said.

More information

For more on Alzheimer's disease, visit the Alzheimer's Association.



SOURCES: Carlos T. Moraes, Ph.D., associate professor, neurology and cell biology and anatomy, University of Miami Miller School of Medicine, Florida; Greg M. Cole, Ph.D., neuroscientist, Greater Los Angeles VA Healthcare System, and associate director, Alzheimer's Disease Research Center, UCLA David Geffen School of Medicine, Los Angeles; Aug. 20-24, 2007, early edition, Proceedings of the National Academy of Sciences


'/>"/>

Copyright©2007 ScoutNews,LLC.

Related medicine news :

1. Gene study links endometriosis, infertility
2. Study reveals how stress can make you sick
3. Study points out that HIV vaccine may not be accepted easily
4. A new study surpasses Gene Therapy Hurdle
5. Tomato Sauce reduces Cancer Risk- Study
6. A question on study of Adult Stem Cell
7. Study on obesity and heart failure
8. National Lung Study in the process
9. Marijuana gateway theory strengthened by study of twins
10. Old theory of adaptation confirmed by new study
11. Study casts doubt on keyboard ills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, FACS , ... Top Doctor. The annual list identifies the nation’s top physicians, in a variety of ... it to the top of Castle Connolly’s coveted ranking. , Castle Connolly is the ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... A global ... has successfully opened clubfoot clinics in all 29 Indian states—bringing the country one step ... in Kangra, Himachal Pradesh, the nonprofit organization is on track to enroll 10,000 children ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... the endoscope after every reprocessing cycle, both between patient procedures and before storage, ... infections. Drying is as important to the prevention of disease transmission and nosocomial ...
(Date:8/16/2017)... ... August 16, 2017 , ... Fusion Flix Inc., a ... programming over four countries and millions of viewers in a partnership with the Amazon ... buy On-Demand and fully available on Blu Ray disc in 2018. Proceeds will be ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery and ... God's love, and all the many ways God shows love to those who ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty ... 2017.  All comparisons, unless otherwise noted, are to the quarter ... Second Quarter 2017 Highlights include: ... of 3.5% Total prescriptions dispensed of 220,000, ... versus 7.6% Gross profit per prescription ...
(Date:8/2/2017)... Aug. 2, 2017 Fenita J. ... as a Pinnacle Lifetime Professional in the Field ... Manager at Turing Pharmaceuticals, AG. Her skills and ... relationship building.                ... 25 years of experience as a highly successful ...
Breaking Medicine Technology: